So far as I know, the prescribing information for the ABCR drugs still states that they are only for the treatment of RRMS--though as I recall Betaseron might have been also listed for progressive forms of MS.
But quite a few neurologists, including a couple I have had, have been prescribing these drugs regardless of the type of MS you have, maybe on the theory that doing something is better than doing nothing. Now they're being advised not to.
Anyway, the American Academy of Neurology (AAN) has come out with 5 recommendations for neurologists, including a recommendation not to
prescribe the ABCR drugs for progressive MS.
An abstract in PubMed, February 23, 2013, gives information about the American Academy of Neurology (AAN)'s "Top Five Recommendations in the Choosing Wisely campaign promoting high-value neurologic medicine and physician-patient communication." The AAN published these recommendations recently in collaboration with the American Board of Internal Medicine Foundation and Consumer Reports.
"A Choosing Wisely Working Group of 10 AAN members was formed to oversee the process and craft the evidence-based recommendations. AAN members were solicited for recommendations, the recommendations were sent out for external review, and the Working Group members (article authors) used a modified Delphi process to select their Top Five Recommendations."
Recommendation #4 states:
The abstract can be seen Only registered and activated users can see links., Click Here To Register....
More information on these recommendations is Only registered and activated users can see links., Click Here To Register....
But quite a few neurologists, including a couple I have had, have been prescribing these drugs regardless of the type of MS you have, maybe on the theory that doing something is better than doing nothing. Now they're being advised not to.
Anyway, the American Academy of Neurology (AAN) has come out with 5 recommendations for neurologists, including a recommendation not to
prescribe the ABCR drugs for progressive MS.
An abstract in PubMed, February 23, 2013, gives information about the American Academy of Neurology (AAN)'s "Top Five Recommendations in the Choosing Wisely campaign promoting high-value neurologic medicine and physician-patient communication." The AAN published these recommendations recently in collaboration with the American Board of Internal Medicine Foundation and Consumer Reports.
"A Choosing Wisely Working Group of 10 AAN members was formed to oversee the process and craft the evidence-based recommendations. AAN members were solicited for recommendations, the recommendations were sent out for external review, and the Working Group members (article authors) used a modified Delphi process to select their Top Five Recommendations."
Recommendation #4 states:
Recommendation 4: Don't prescribe interferon-β or glatiramer acetate to patients with disability from progressive, nonrelapsing forms of multiple sclerosis.
More information on these recommendations is Only registered and activated users can see links., Click Here To Register....

s
Comment